All news

Legend Biotech Q3 revenue rises 32% to $359.5 million as Carvykti sales jump 36%

Rallies.ai · · AI-summarised by FinFlash

Legend Biotech reported third-quarter revenue up 32% to $359.5 million and adjusted net income of $55.6 million, swinging from an adjusted loss of

So What?

Sustained Carvykti growth supports Legend and the CAR-T segment, and adds to Johnson & Johnson's oncology momentum.

Read original source

JNJ company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.